Patients with atrial fibrillation receiving the factor XI inhibitor abelacimab have a lower risk for bleeding than those receiving rivaroxaban, irrespective of age, a phase 2b study finds.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/factor-xi-inhibitor-abelacimab-cuts-bleeding-risk-across-age-2026a10004iw?src=rss
Author :
Publish date : 2026-02-12 12:46:00
Copyright for syndicated content belongs to the linked Source.